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The aim of the present study was to assess the diagnostic usefulness of Fluorine-18 ﬂuorodeoxyglucose 
(18F-FDG) positron emission tomography/computed tomography (PET/CT) in the prediction of local 
recurrence of malignant lung tumors by analyzing the pre-radiofrequency ablation (RFA) maximal 
standardized uptake value (SUVmax).  We performed a historical cohort study of consecutive malignant 
lung tumors treated by RFA from January 2007 to May 2008 at Okayama University Hospital.  We 
selected only lung tumors examined by PET/CT within 90 days before RFA and divided them (10 pri-
mary and 29 metastatic) into 3 groups according to their tertiles of SUVmax.  We calculated recurrence 
odds ratios in the medium group and the high group compared to the low group using multivariate 
logistic analysis.  After we examined the relationship between SUVmax and recurrence in a crude model,  
we adjusted for some factors.  Tumors with higher SUVmax showed higher recurrence odds ratios 
(medium group; 1.84,  high group; 4.14,  respectively).  The tumor size also increased the recurrence 
odds ratio (2.67); we thought this was mainly due to selection bias because we excluded tumors less 
than 10mm in diameter.  This study demonstrated the pre-RFA SUVmax in PET/CT may be a prognos-
tic factor for local recurrence of malignant lung tumors.
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adiofrequency ablation (RFA) is a thermal 
therapy that results in coagulation tumor necro-
sis and can be used to treat malignant lung tumors.  
Preliminary studies of the use of RFA to treat lung 
tumors have shown promising results for initial local 
control in carefully selected patient populations 
[1-6].
　 Fluorine-18 ﬂuorodeoxyglucose (18F-FDG) positron 
emission tomography/computed tomography (PET/
CT) is a noninvasive,  convenient,  and feasible tool 
that is now integral to the management of various 
cancers.  PET/CT is also a valuable technique for 
evaluating local control after radiotherapy or prognos-
tic long-term outcome after surgery,  chemotherapy or 
radiotherapy for several cancers [7-13].  This use is 
sometimes even more important than its ability to be 
used as an anatomic imaging modality to detect distant 
metastases and identify remote recurrent disease 
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[14].
　 The standardized uptake value (SUV) of FDG is 
the ratio of activity in tissue per unit volume to the 
activity in the injected dose per patient body weight,  
and it is widely used because of its simplicity.  The 
SUVmax is the maximal value of the SUV in a tumor 
section.
　 It has been reported that the increased expression 
of glucose transporters in malignant cells may be 
associated with a higher metabolism and increased 
rates of glucose utilization in non-small cell lung can-
cer [15]; therefore,  tumor proliferation,  progres-
sion and metastasis are associated with the SUV [16,  
17].  This indicates that the SUVmax might reﬂect the 
malignant potential in lung tumors.
　 The aim of this study was to assess the diagnostic 
utility of PET/CT for the prediction of local tumor 
recurrence by analyzing the pre-RFA SUVmax in pri-
mary lung cancers or metastatic malignant lung 
tumors.
Materials and Methods
　 The institutional review board of Okayama 
University Hospital approved the study and informed 
consent was obtained from all patients before they 
underwent lung RFA.
　 The method used for patient selection is shown in 
Fig.  1.  This study included 251 consecutive lung 
tumors that were treated by lung RFA with multi-
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Treated by lung RFA 2007/1-2008/5: 251 tumors, 118 patients NOT ASSESED FOR ELIGIBIBITY:
Not investigated with PET/CT scans within 90 days
before lung RFA : 133 tumors, 46 patients
Investigated with PET/CT scans 
within 90 days before lung RFA : 118 tumors, 72 patients
EXCLUDED:
Tumor diameter < 10mm or less : 
16 tumors, 4 patients
Tumor diameterｧ10mm or more : 102 tumors, 68 patients EXCLUDED:
Tumor was treated by monopolar needle (Cool-tip) : 
24 tumors, 16 patientsTumor was treated by expandable needle (LeVeen) : 
78 tumors, 52 patients EXCLUDED:
Tumor was incompletely ablated :
3 tumors, 3 patients
Tumor was completely ablated : 75 tumors, 49 patients
EXCLUDED:
Tumor was treated with radiotherapy before or after 
RFA : 8 tumors, 6 patientsNot treated with radiotherapy before or after RFA : 
67 tumors, 43 patients
EXCLUDED:
Follow up duration < 24 months : 
28 tumors, 13 patientsFollow up duration >24 months : 39 tumors, 30 patients
Recurrence group : 
9 tumors, 9 patients
Non-recurrence group : 
30 tumors, 22 patients
Fig. 1　A ﬂowchart depicting the patient selection.  ※Sometimes there were multiple nodules in the same patient.
tined expandable electrodes from January 2007 to 
May 2008 at Okayama University Hospital.  We then 
selected only tumors that were investigated using 
PET/CT scans within 90 days before lung RFA.  
Whole-body pre-RFA PET/CT was performed as a 
routine examination for most of these patients.  We 
excluded tumors less than 10mm in diameter (their 
maximum diameters were measured on pulmonary 
window setting CT images).  We also excluded tumors 
ablated with a single internally cooled electrode 
(Cool-tip; Covidien,  Mansﬁeld,  MA,  USA),  ablated 
incompletely,  or treated with radiotherapy before or 
after RFA.  Some patients underwent systemic chemo-
therapy before lung RFA (14 patients,  20/39 tumors) 
or after lung RFA (11 patients,  15/39 tumors).  We 
did not exclude these tumors treated by chemotherapy 
before and after RFA.  No concurrent chemotherapy 
was administered within the treatment period of the 
lung RFA.  For the recurrent group,  we stopped fol-
lowing up patients when tumor recurrence was found.  
For the non-recurrent group,  we excluded tumors for 
which the follow-up duration was less than 24 
months; in order to distinguish non-recurrent tumors 
from recurrent tumors.  The mean follow-up duration 
was 29.5±4.1 mo (range,  24.1-36.7 mo) in the nonre-
currence group.  Finally,  the selected tumors con-
sisted of 10 primary lung cancers and 29 metastatic 
malignant lung tumors (mean size,  16.4mm).  The 
patients consisted of 17 males and 12 females (mean 
age,  68.0 years).
　 Those tumors comprised 5 tumor types: primary 
lung cancer (n＝10),  pulmonary metastases from lung 
cancer (n＝3),  colorectal cancer (n＝19),  hepatocel-
lular carcinoma (n＝5),  and leiomyosarcoma (n＝2).  
The characteristics of the patients are summarized in 
Table 1.
　 PET/CT was performed a mean of 19.3±21.7 d 
(range 1-83 d) before lung RFA,  using a PET/CT 
scanner (Biograph LSO/Sensation 16,  Siemens,  
Munich,  Germany).  After fasting for at least 5h,  
patients were injected with 3.7MBq (megabecquerel) 
of 18F-FDG per kg (kilogram) of body weight,  and 
images were acquired 1.5h later.  On arrival at our 
hospital,  their serum glucose was checked before 18F-
FDG injection,  and was less than 200mg/dl in all 
patients.  Emission scanning was performed from the 
skull base to the proximal thigh,  and afterward,  the 
CT scanned voxel value was used for attenuation cor-
rection.  Images were reconstructed using an iterative 
reconstruction algorithm (ordered-subset expectation 
maximization: OSEM).  The technical parameters for 
the 16-detector row helical CT included a section 
thickness of 3mm in the soft tissue window and 5mm 
in the lung window,  a pitch factor of 0.8 (1.5mm×16 
collimation,  mm/rotation＝19.2) and a gantry rotation 
speed of 0.5 s (Care dose 4D,  50mAs).
　 For the regions of interest (ROI),  the images were 
transferred to the workstation (Fujin-Raijin,  AZE 
Inc.,  Tokyo,  Japan),  and FDG-PET scans were ana-
lyzed by 2 experienced nuclear physicians who were 
blinded to the histopathological ﬁndings and clinical 
follow-up data.  To evaluate the 18F-FDG uptake,  they 
drew ROI for tumors and measured the SUVmax in each 
ROI using the Fujin-Raijin software program.
　 During the follow-up,  CT or PET/CT was per-
formed approximately 1,  3,  6,  9,  12 and then every 
6 months after lung RFA.  Local control was evaluated 
with CT.  We compared the tumor size and the geom-
etry of the ablation zone with the previous CT images.  
Local tumor progression was considered to have 
occurred when the ablation zone was circumferentially 
enlarged compared to the previous CT images.  The 
appearance of an irregular,  scattered,  nodular,  or 
eccentric focus in the ablation zone on contrast-
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Table 1　 Characteristics of the patients
Gender (the number of patients)





Histology (the number of tumors)
　Primary Lung Neoplasm (10)
　　Squamous 1
　　Adenocarcinoma 5
　　NSCLC1,  not speciﬁed 4










1NSCLC,  Non-small cell lung cancer.
enhanced CT was also considered to indicate local 
progression [4,  18].
　 We calculated the SUVmax and tumor size for each 
tumor.  To assess to what extent the other most often-
quoted prognostic factors have an eﬀect on tumor 
recurrence,  we added 6 other major tumor character-
istics which might have aﬀected the tumor recurrence,  
including: age,  sex (male or female),  chemotherapy 
(yes or no),  primary or metastatic disease,  the inter-
val between PET/CT and RFA execution,  and prox-
imity (yes or no; whether or not a tumor was in con-
tact with a large blood vessel or bronchus; if those 
tumors were contiguous with a vessel of diameterｧ
3mm or a bronchus with an inner diameterｧ2mm,  we 
considered the tumor to have proximity) to the statis-
tical analyses.
　 Statistical analysis. We divided the tumors 
into 3 groups according to the tertile of the SUVmax 
value,  a low group (SUVmaxｦ2.54),  medium group 
(2.54＜SUVmaxｦ4.61) and a high group (SUVmaxｧ
4.61) and performed a descriptive statistical analysis 
of the tumor characteristics.  We calculated the odds 
ratios and their 95ｵ conﬁdence intervals for recur-
rence in the tumor group with high SUVmax values 
compared to the tumor group with low SUVmax values 
using multivariate logistic regression analysis.  After 
we examined the relationship between SUVmax and 
recurrence in a crude model,  we adjusted for sex and 
age (model 1),  proximity (model 2),  and,  ﬁnally,  
tumor size (model 3).  We also calculated the 
Spearmanʼs correlation coeﬃcient between the tumor 
size and SUVmax.
　 We considered a p-value＜0.05 (two-sided test) to 
be a statistically signiﬁcant diﬀerence.  All statistical 
analyses were performed by using the SPSS 17.0 for 
Windows software package (SPSS,  Inc.,  Chicago,  
IL,  USA).
Results
　 During the follow-up period,  tumor recurrences 
were observed in 9 of 39 tumors (23.1ｵ).  Three 
recurrences occurred within the ﬁrst 6 months,  
another 5 within the next 6 months,  and 1 at 31 
months after lung RFA.
　 Among the 3 tumor groups established according to 
the SUVmax values,  only the tumor size was signiﬁ-
cantly diﬀerent (Table 2).
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Yes 9 9 10
0.88No 4 4 3
Tumor size (mm) Mean±SD 13.9±6.1 16.9±5.5 18.5±7.7 0.049＊
Primary or 
metastatic
Primary 4 3 3
0.88Metastatic 9 10 10
PET/CT-RFA
interval (days) Mean±SD 29.8±29.4 16.8±15.7 11.3±13.5 0.41
Proximity
Yes 1 2 3 0.56
No 12 11 10
Recurrence
Yes 1 3 5 0.18
No 12 10 8
PET/CT,  positron emission tomography/computed tomography; RFA,  radiofrequency ablation; SD,  standard deviation; SUVmax,  maximal 
standardized uptake value.
P-values were calculated using the upper-sided Kruskal-Wallis test and p＜ .05 was considered to represent statistical signiﬁcance,  as 
indicated by＊.
　Adjusting for sex,  age,  proximity,  and tumor size,  
we found that higher SUVmax was associated with 
higher odds ratios for recurrence (medium group:  
1.84; high group: 4.14) compared with the low group 
(Table 3,  model 3).  Other factors that increased the 
odds ratios for recurrence were gender (being male;  
odds ratios＝4.38) and tumor size (odds ratio＝2.67),  
although their 95ｵ conﬁdence intervals were quite 
wide.  Regarding age and proximity,  however,  we 
found no clear association with the odds ratios for 
recurrence (odds ratios＝1.06,  0.84,  respectively).
　 The Spearmanʼs correlation coeﬃcient between the 
tumor size and SUVmax was 0.456 (p＝0.004),  indicat-
ing that the tumor size and SUVmax were in moderate 
correlation.  Fig.  2A and 2B show a recurrence case,  
whereas Fig.  3A and 3B show a non-recurrence case.
Discussion
　 In many institutes,  18F-FDG PET/CT has been 
used to assess the presence of whole body metastases 
before and after lung RFA.  Although the SUVmax has 
been suggested to be helpful in predicting the risk of 
local recurrence after radiotherapy in lung cancer and 
other several cancers [7,  8],  it has not been fully 
veriﬁed whether the pre-RFA SUVmax is capable of 
predicting the risk of local recurrence after lung 
RFA.  This historical cohort study examined whether 
the pre-RFA SUVmax can be useful to predict the risk 
of local recurrence after lung RFA.  We demonstrated 
that,  in addition to its original diagnostic purpose,  
18F-FDG PET/CT could also provide a prognostic 
factor for local tumor recurrence after lung RFA.  
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Fig. 2　 A,  Pre-RFA PET/CT of a 77-year-old male with local recurrence.  The PET/CT showed primary lung cancer (adenocarcinoma) 
in the right lower lobe (oblique arrow).  This tumor was treated by RFA.  The SUVmax of the tumor was 3.89; B,  The follow-up CT examina-
tion was performed 9 months after RFA.  The contrast-enhanced CT showed local tumor progression.  The ablation zone was circumferen-
tially enlarged.  Also,  an irregular focus appeared in the ablation zone on contrast-enhanced CT (arrow head).
Table 3　 Odds ratios and 95% conﬁdence intervals for recurrence
Crude model Model 1 Model 2 Model 3
OR　　(95% CI) OR　　(95% CI) OR　　(95% CI) OR　　(95% CI)
SUVmax Low 1.00　　　　　　 1.00　　　　　　 1.00　　　　　　 1.00　　　　　　
Medium 3.60　(0.32-40.23) 2.22　(0.18-28.18) 2.25　(0.17-29.41) 1.84　(0.13-25.41)
High 7.50　(0.73-76.77) 5.26　(0.45-62.12) 5.33　(0.43-65.62) 4.14　(0.31-54.44)
Sex Male 4.35　(0.36-52.69) 4.33　(0.36-52.69) 4.38　(0.38-50.58)
Age (1 year) 1.06 　(0.94-1.21) 1.07 　(0.94-1.21) 1.06 　(0.94-1.20)
Proximity 0.94 　(0.11-8.17) 0.84 　(0.09-7.77)
Tumor sizeｧ15mm 2.67　(0.39-18.54)
CI,  conﬁdence interval; OR,  odds ratio; SUVmax,  maximal standardized uptake value.
This result was in agreement with a similar study by 
Singnurkar et al.  [20].  Our study was performed 
strictly using only subjects whose tumors were treated 
with a LeVeen Needle Electrode (Boston Scientiﬁc 
Japan Corp.,  Tokyo,  Japan).  We also reviewed the 
most eﬀective prognostic factors of those currently 
reported and investigated their prognostic value in 
predicting local tumor recurrence.
　 Hiraki T.  et al.  previously reported that the over-
all local control rates of malignant primary lung can-
cer and pulmonary metastasis after lung RFA were 
97ｵ,  86ｵ,  81ｵ,  and 76ｵ at 6,  12,  18,  and 24 
months,  respectively [19].  In other words 24ｵ of 
malignant lung tumors recur within 2 years after 
RFA.
　 Although pre-RFA 18F-FDG uptake in lung tumors 
might not be a direct indicator of residual micro-
metastases after RFA,  we expected that 18F-FDG 
uptake might be correlated with the malignant poten-
tial of tumor cells.  The pre-RFA SUVmax in tumors 
reﬂects their glucose metabolism,  which is facilitated 
in the most malignant tumors.  This parameter may 
lead to a better understanding of the malignant poten-
tial of the tumor,  and therefore,  can be used to pre-
dict the risk of local tumor recurrence after lung 
RFA.  Our results indicate that when the pre-RFA 
SUVmax is high,  the risk of recurrence is high.
　 The other factors associated with higher odds 
ratios for recurrence were gender (being male; odds 
ratio＝4.38) and tumor size (odds ratio＝2.67).  With 
regard to the tumor size,  we calculated the odds ratio 
for the recurrence of tumors with a diameterｧ15mm 
compared to tumors with a diameter＜15mm.  Note 
that,  however,  there were many tumors from male 
patients in the recurrence group (8/9) and that there 
were only 2 tumors of＜15mm in the recurrence 
group (2/9) because tumors＜10mm in diameter were 
excluded from this study.  Thus,  the present ﬁndings 
should be carefully interpreted in light of a possible 
selection bias.
　 Various studies have shown that tumor size is a 
very important factor in predicting the local control of 
lung tumors after RFA [20-23].  Many studies have 
also reported that the SUVmax values of tumors are 
associated with their pathological diameter [24-26].  
This may indicate that the SUVmax and the tumor size 
measured on CT will be correlated.  A Spearmanʼs 
test of our present data supported this hypothesis,  
and showed that the tumor size and SUVmax had a 
moderate correlation (correlation coeﬃcient＝0.456,  
p＝0.004).
　 There were several limitations to this study.  First,  
all of the cases of primary lung cancer were diagnosed 
on the basis of histological evidence.  However,  most 
of the cases of pulmonary metastases were diagnosed 
only by CT without histological evidence; they had 
surgically or biopsy-proven primary cancers,  and the 
diagnoses of lung metastasis and local progressions 
after RFA were only based on radiological images.  
The second limitation is that the number of cases was 
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Fig. 3　 A,  Pre-RFA PET/CT of a 67-year-old male without local recurrence.  The PET/CT showed a metastatic lesion in the left lung 
from primary rectal cancer (oblique arrow).  The metastatic tumor was treated by RFA.  The SUVmax in the tumor was 2.36; B,  The follow-
up CT examination was performed 25 months after RFA.  The contrast-enhanced CT shows no irregular enhancement (arrow head).
small because we enforced strict selection criteria.  
We excluded tumors＜10mm in diameter (their maxi-
mum diameters were measured on pulmonary window 
setting CT images) because we could not reliably 
measure the SUVmax in such small tumors.  In addition,  
although we excluded some tumors that were treated 
with a mono-polar needle,  ablated incompletely,  or 
were also treated with radiotherapy before or after 
RFA,  this selection was necessary to equalize the 
experimental conditions.  If we included tumors that 
were ablated under diﬀerent conditions,  the biological 
behavior of these tumors might modify the study 
results in such a small population.  In addition,  the 
eﬀects of radiotherapy would potentially make a sig-
niﬁcant impact on the local control of lung tumors.  
The third limitation is that ablation factors,  such as 
the maximum power,  the ablation time,  and the num-
ber of overlapping ablations,  were not evaluated in the 
investigation of risk factors for local tumor progres-
sion.  Although our ablation algorithm varies according 
to tumor size (thus according to the array diameter of 
the electrodes),  almost all tumors (38/39) were 
treated using the same ablation technique.  Therefore,  
the ablation conditions for each tumor were similar.  
Another possible limitation is that the selected tumors 
included varied histological types in this study.  
However,  Hiraki T.  et al.  reported that the tumor 
type per se did not signiﬁcantly inﬂuence the local 
control [19].  We did not adjust any of the study data 
based on the diﬀerences between tumor types.
　 In conclusion,  this study demonstrated that the 
SUVmax determined using PET/CT may be an eﬀec-
tive new prognostic factor for tumor recurrence after 
lung RFA.  We believe that 18F-FDG PET can be 
performed as a pre-RFA risk evaluation for local 
tumor recurrence after RFA,  rather than just for the 
detection of whole body metastasis.
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